← Evidence map

ArticleFrontiers in immunology2026

Correction: Efficacy and safety of camrelizumab plus apatinib for solid tumors: a meta-analysis.

Ping Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 42865897